$300,000 in Research Grants Awarded as Part of its Ongoing Annual Research Awards Program
TEMPE, Ariz., June 02, 2025--(BUSINESS WIRE)--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the award of twelve research grants to universities under the company’s fifteenth Annual Research Award Program.
"Align is pleased to grant the following research awards that will lead to insights and evidence that advance the science and applicability of treatment for patients of all ages," said Dr. Mitra Derakhshan, Align executive vice president, chief clinical officer, global treatment planning and clinical services. "We are excited to support university research around the world, and we continue to learn about the findings from the awarded research and their publications."
The Americas research award recipients for 2025 are:
The European research award recipients for 2025 are:
The Asia Pacific research award recipients for 2025 are:
"This year the number of applications to the program is the largest since its initiation fifteen years ago," said John Morton, Align vice president, technical fellow. "The research endeavors funded by this highly competitive program may advance the science of dentistry and aim to improve the dental care of the global community. We are proud to provide this opportunity to these excellent university researchers throughout the world."
The funded research studies cover a wide range of topics, including:
All award applications received were first reviewed and prioritized in a blind evaluation by an independent academic committee. The final recipients were then determined by Align Technology.
About Align Technology, Inc.
Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and are key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.
For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.
Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250602024927/en/
Contacts
Align Technology
Madelyn Valente
(909) 833-5839
mvalente@aligntech.com
Zeno Group
Sarah Karlson
(828) 551-4201
sarah.karlson@zenogroup.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.